UK on Brexit Implications: ‘Significant Benefits’ to Remain Part of EMA
By Zachary Brennan -
Published 14 March 2017
The UK government’s EU External Affairs Subcommittee on Tuesday published a report on the implications of Brexit on trade, noting that there may be “significant benefits” in continuing UK participation in the European Medicines Agency (EMA).
Categories: News, Europe, EC, EMA, MHRA, NICE, Biologics and biotechnology, Drugs
Tags: Brexit, UK in EMA, House of Lords